Treatment Guidelines - Issue 131 | The Medical Letter Inc.

Treatment Guidelines from The Medical Letter

FROM
ISSUE

131

July 1, 2013

View Complete Issue Table of Contents 2019

Issue 131

Drugs for Bacterial Infections

Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.

Drugs for Bacterial Infections

July 1, 2013 (Issue: 131)

The text that follows reviews some common bacterial infections and their empiric treatment pending the results of culture and susceptibility testing. The recommendations made here are based on the results of susceptibility studies, clinical...more

Show References Hide References

1. DA Talan et al. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin Infect Dis 2011; 53:144.

2. SD Kobayashi and FR DeLeo. An update on community-associated MRSA virulence. Curr Opin Pharmacol 2009; 9:545.

3. C Liu et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:285.

4. Ceftaroline fosamil (Teflaro) - a new IV cephalosporin. Med Lett Drugs Ther 2011; 53:5.

5. BA Lipsky et al. 2012 Infectious Disease Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2012; 54:e132.

6. B Spellberg and BA Lipsky. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis 2012; 54:393.

7. I Byren et al. Pharmacotherapy of diabetic foot osteomyelitis. Expert Opin Pharmacother 2009; 10:3033.

8. I García-De La Torre and A Nava-Zavala. Gonococcal and nongonococcal arthritis. Rheum Dis Clin North Am 2009; 35:63.

9. DR Osmon et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2013; 56:e1.

10. JR Samuel and FK Gould. Prosthetic joint infections: single versus combination therapy. J Antimicrob Chemother 2010; 65:18.

11. AWChow et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis 2012; 54:e72.

12. A Zalmanovici and J Yaphe. Intranasal steroids for acute sinusitis. Cochrane Database Syst Rev 2009; 4:CD005149.

13. ST Shulman et al. Clinical practice guidelines for the diagnosis and management of Group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis 2012; 55:1279.

14. AL Myers et al. Genetic commonality of macrolide-resistant group A beta hemolytic streptococcus pharyngeal strains. Ann Clin Microbiol Antimicrob 2009; 8:33.

15. J Aspa et al. Pneumococcal antimicrobial resistance: therapeutic strategy and management in community-acquired pneumonia. Expert Opin Pharmacother 2008; 9:229.

16. LA Mandell et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2: S27.

17. AD Mosholder et al. Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med 2013; 368:1665.

18. AN Kieninger and PA Lipsett. Hospital-acquired pneumonia: pathophysiology, diagnosis, and treatment. Surg Clin North Am 2009; 89:439.

19. LE Nicolle et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005; 40:643.

20. K Gupta et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52:e103.

21. K Gupta et al. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med 2007; 167:2207.

22. ME Falagas et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010; 65:1862.

23. TM Hooton. Uncomplicated urinary tract infection. N Engl J Med 2012; 366:1028.

24. AM Macejko and AJ Schaeffer. Asymptomatic bacteriuria and symptomatic urinary tract infections during pregnancy. Urol Clin North Am 2007; 34:35.

25. AB Murphy et al. Chronic prostatitis: management strategies. Drugs 2009; 69:71.

26. JS Solomkin et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:133.

27. GE Stein and T Babinchak. Tigecycline: an update. Diagn Microbiol Infect Dis 2013; 75:331.

28. P Prasad et al. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54:1699.

29. FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. Available at http://www.fda.gov. Accessed June 5, 2013.

30. LV McFarland. Renewed interest in a difficult disease: Clostridium difficile infections—epidemiology and current treatment strategies. Curr Opin Gastroenterol 2009; 25:24.

31. SH Cohen et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431.

32. CM Surawicz et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108:478.

33. Treatment of Clostridium difficile infection. Med Lett Drugs Ther 2011; 53:14.

34. TJ Louie et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422.

35. Fidaxomicin (Dificid) for Clostridium difficile infection. Med Lett Drugs Ther 2011; 53:73.

36. KS Kim. Acute bacterial meningitis in infants and children. Lancet Infect Dis 2010; 10:32.

37. D van de Beek et al. Nosocomial bacterial meningitis. N Engl J Med 2010; 362:146.

38. F Allerberger and M Wagner. Listeriosis: a resurgent foodborne infection. Clin Microbiol Infect 2010; 16:16.

39. Cephalosporins for patients with penicillin allergy. Med Lett Drugs Ther 2012; 54:101.

40. D van de Beek et al. Corticosteroids for acute bacterial meningitis (Review). Cochrane Database Syst Rev 2007; 1:CD004405.

41. RP Dellinger et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013; 41:580.

42. ST Micek et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother 2010; 54:1742.

43. B Hoen and X Duval. Clinical practice. Infective endocarditis. N Engl J Med 2013; 368:1425.

44. AG Freifeld et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:e56.

45. JLWang and PR Hsueh. Therapeutic options for infections due to vancomycin-resistant enterococci. Expert Opin Pharmacother 2009; 10:785.

46. NY Lee et al. Carbapenem therapy for bacteremia due to extended-spectrum-beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility. Antimicrob Agents Chemother 2012; 56:2888.

47. JJ Fong et al. Clinical outcomes with ertapenem as a first-line treatment option of infections caused by extended-spectrum beta-lactamase producing gram-negative bacteria. Ann Pharmacother 2012; 46:347.

48. EA Neuner et al. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother 2012; 56:5744.

49. A Michalopoulos et al. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 2010; 16:184.

50. CH Kvitko. Polymyxin B versus other antimicrobials for the treatment of Pseudomonas aeruginosa bacteraemia. J Antimicrob Chemother 2011; 66:175.

51. RE Mendes et al. Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005-2009). Diagn Microbiol Infect Dis 2010; 68:307.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.